5) 나이 환자에서 흡입지속성항콜린제 또는 흡입지속성베타-2작용제를 사용하는 중에 급성악화 를 경험하거나 mMRC 2단계 이상의 호흡곤란이 지속되는 경우 흡입지속성항콜린제와 흡입 지속성베타-2작용제(흡입24시간지속성베타-2작용제 포함)를 병용한다(근거수준: 낮음, 권 고강도: 강함).

### 근거표 5; LABA + LAMA vs LAMA

| 연구수 | 연구설계   | 비뚤림 위험 | 비일관성 | 비직접성 | 비정밀 | 출판 비뚤림 | 근거수준 |
| :----- | :--------- | :---------- | :------- | :------- | :----- | :---------- | :------- |
| 2      | 무작위대조군 | 없음        | 있음     | 있음     | 있음   | 없음        | 낮음     |

| Field                    | Description                                                                                                                                                                                                                                                                                                                                                           |
| :----------------------- | :-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Author, year publication | Donald A Mahler et al., 2012                                                                                                                                                                                                                                                                                                                                          |
| Title                    | Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison                                                                                                                                                                                            |
| Country                  | Study 1: 186 centers in 14 countries                                                                                                                                                                                                                                                                                                                                  |
| Setting/Design           | Double-blind tiotropium 18 µg+Indacaterol 150 µg once daily vs. tiotropium 18 µg+placebo                                                                                                                                                                                                                                                                               |
| Time frame               | 12-week study                                                                                                                                                                                                                                                                                                                                                         |
| Randomization method     | An automated interactive voice response system and was stratified by COPD severity                                                                                                                                                                                                                                                                                    |
| Allocation concealment   | Yes (An automated interactive voice response system)                                                                                                                                                                                                                                                                                                                  |
| Blinding                 | The blinding of indacaterol and placebo continued until the study                                                                                                                                                                                                                                                                                                     |
| - Participants           | Yes                                                                                                                                                                                                                                                                                                                                                                   |
| - Investigators          | Yes                                                                                                                                                                                                                                                                                                                                                                   |
| - Outcome assessors      | Yes                                                                                                                                                                                                                                                                                                                                                                   |
| Intention-to-treat       | Yes                                                                                                                                                                                                                                                                                                                                                                   |
| Follow-up period         | 12-week                                                                                                                                                                                                                                                                                                                                                               |
| Loss to follow-up        | 39/570 for indacaterol+tiotropium, 35/561 for tiotropium+placebo group                                                                                                                                                                                                                                                                                                |
| ITT anlaysis             |                                                                                                                                                                                                                                                                                                                                                                       |

| Field                        | Indacaterol+tiotropium | Placebo+tiotropium |
| :--------------------------- | :--------------------- | :----------------- |
| Number                       | 570                    | 561                |
| Age                          | 64.0±9.07              | 63.4±9.22          |
| Sex (M)                      | 70%                    | 67%                |
| Ethnicity (Caucasian)        | 78.2                   | 76.8               |
| FEV₁ %predicted (postBD)\*   | 48.3 (9.70)            | 48.9 (11.46)       |
| FEV₁/FVC (postBD)\*          | 46.4 (9.74)            | 45.8 (10.00)       |
| FEV₁ reversibility (%)\*     | 16.5 (14.48)           | 17.3 (17.13)       |

Inclusion
- aged ≥40 years
- a smoking history of ≥10 pack yrs
- a diagnosis of moderate-to-severe COPD (postbronchodilator 30≤FEV₁<65, FEV₁/FVC<0.7)

Exclusion
- A history of asthma
- History of exacerbation within the previous 6 weeks

Intervention

| Group                  | Dosage                                |
| :--------------------- | :------------------------------------ |
| Indacaterol+tiotropium | Indacaterol 150 µg once daily         |
|                        | Tiotropium, 18 µg once daily          |
| Placebo+tiotropium     | tiotropium, 18 µg once daily          |

Result
Number: Indacaterol+tiotropium 570, Placebo+tiotropium 561

Differences between indacaterol+tio vs. tio+placebo

| Result Item                       | Value (mL) |
| :-------------------------------- | :--------- |
| FEV₁ AUC 5 min~8 h                | 120 (90~160) |
| COPD severity - moderate          | 130 (100~160) |
|             - severe              | 120 (90~150) |
| Smoking status - ex smoker        | 130 (100~170) |
|                 - current smoker  | 120 (90~160) |
| ICS use - non-users               | 120 (90~160) |

<PAGE>108